-
1 month ago | 
ajmc.com | Cameron Santoro |Lawrence F. Eichenfield
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Lawrence F.
-
1 month ago | 
ajmc.com | Cameron Santoro |Lawrence F. Eichenfield
This content was produced independently by The American Journal of Managed Care® (AJMC®) and is not endorsed by the American Academy of Dermatology. Lawrence F. Eichenfield, MD, FAAD, chief of pediatric and adolescent dermatology at Rady Children's Hospital and professor of dermatology and pediatrics and vice chair of the department of dermatology at the University of California San Diego School of Medicine, emphasized that shared decision-making is paramount in atopic dermatitis management.
-
1 month ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this exclusive video, Lawrence F. Eichenfield, MD, a member of the Healio Dermatology Peer Perspective Board, discusses psoriasis case reports presented at Maui Derm 2025.
-
1 month ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego, discusses areas of unmet need in the field of psoriasis.
-
1 month ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, discusses oral treatments available to pediatric and adolescent psoriasis discussed at Maui Derm 2025. “From a systemic agent standpoint, we’ve never had an oral agent approved for psoriasis,” Eichenfield, who is chief of pediatric and adolescent dermatology at Rady Children’s Hospital-San Diego and vice chair of the department of dermatology at University of California, San Diego, told Healio.
-
2 months ago | 
healio.com | Lawrence F. Eichenfield |Erin Michael |Kristen Dowd
In this Healio exclusive video, Lawrence F. Eichenfield, MD, talks about takeaways in updates on topical treatments for pediatric and adolescent psoriasis discussed at Maui Derm 2025.
-
Oct 23, 2024 | 
jamanetwork.com | Amy S. Paller |Pedro Mendes-Bastos |Elaine Siegfried |Lawrence F. Eichenfield
Key PointsQuestion
Is the efficacy of upadacitinib maintained with long-term treatment with an acceptable adverse event profile in adolescents with moderate to severe atopic dermatitis?
-
Sep 18, 2024 | 
jamanetwork.com | Eric Simpson |Lawrence F. Eichenfield |Javier Alonso-Llamazares
Key PointsQuestion What is the efficacy and safety of once-daily roflumilast cream, 0.15%, in patients with atopic dermatitis (AD)? Findings In 2 phase 3 randomized clinical trials of 1337 individuals with AD, significantly more patients treated with once-daily roflumilast cream, 0.15%, achieved Validated Investigator Global Assessment for Atopic Dermatitis success at 4 weeks than patients treated with vehicle cream. Roflumilast was well tolerated with low rates of adverse events in both trials.
-
May 9, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Lawrence F. Eichenfield
You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: By week 8, a higher proportion of patients who applied ruxolitinib cream 1.5% vs. vehicle achieved IGA treatment success (50.6% vs. 14%). Through 52 weeks of treatment, no serious adverse events were reported.
-
Mar 4, 2024 | 
healio.com | Gabrielle Capaldo |Kristen Dowd |Lawrence F. Eichenfield
You've successfully added Dermatitis to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Key takeaways: Changes in the aryl hydrocarbon receptor (AhR) are associated with atopic dermatitis. The efficacy of tapinarof, an AhR agonist, validates the targeting of AhR as a novel approach.
